Methylene blue, an old drug with new indications?
2010 (English)In: Jurnalul Roman de Anestezie Terapie Intaensiva, ISSN 1582-652X, Vol. 17, no 1, 35-41 p.Article, review/survey (Other academic) Published
Just when we thought we finally understood methylene blue (MB) after it has been used clinically for more than a century, the old properties are revived and therefore possible new indications appears. Nitric oxide (NO) stimulates soluble guanylate cyclase, which converts guanosine triphosphate into cyclic guanosine monophosphate. Increases in cGMP concentration, in turn, through a cascade of protein kinases, induce smooth muscle relaxation and vasodilation. Methylene blue (MB) has direct inhibitory effects on nitric oxide synthases (NOS), both constitutive and inducible and blocks accumulation of cyclic guanosine monophosphate (cGMP) by inhibiting the enzyme guanylate cyclase. Also, MB blocks the iron-containing enzymes such as xanthine oxidase and has antioxidants effects. New indications are therefore described in relation with MB as in the vasoplegic syndrome following cardiopulmonary bypass in humans and in the settings of cardiac arrest in animals.
Place, publisher, year, edition, pages
2010. Vol. 17, no 1, 35-41 p.
methylene blue, oxidative injury, neuroprotection, hemodynamics, cardiopulmonary resuscitation
albastru de metilen, leziune oxidativă, neuroprotecţie, hemodinamică, resuscitare cardiopulmonară
Anesthesiology and Intensive Care
Research subject Anaesthesiology and Intensive Care
IdentifiersURN: urn:nbn:se:uu:diva-128811OAI: oai:DiVA.org:uu-128811DiVA: diva2:331724
Romanian journal2010-07-262010-07-242010-08-19Bibliographically approved